Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML1KSA)

• Drug Name: GMI-1359 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DML1KSA

Molecule-Related Drug Atlas

Drug(s) Targeting E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
GMI-1271	DMDTGWQ	Acute myeloid leukaemia	2A60	Phase 3	[5]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[6]
Bimosiamose	DM0TH9A	Atopic dermatitis	EA80	Phase 2a	[7]
PF-07209326	DM7YRAL	Sickle-cell disorder	3A51	Phase 1	[8]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[9]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[10]
O-Sialic Acid	DMCAR7B	Discovery agent	N.A.	Investigative	[11]
Efomycine M	DMOKX76	Discovery agent	N.A.	Investigative	[12]
1na	DM0A1YI	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Plerixafor	DMCJN1P	Non-hodgkin lymphoma	2B33.5	Approved	[13]
Motixafortide	DMW34B1	Multiple myeloma	2A83	Approved	[14]
Ulocuplumab	DM6PMNR	Multiple myeloma	2A83	Phase 3	[15]
Balixafortide	DMUOFAC	Metastatic breast cancer	2C6Y	Phase 3	[16]
AMD-070	DMVOY6B	Whim syndrome	4A00.Y	Phase 3	[17]
TG-0054	DM2ZLWH	Macular degeneration	9B78.3	Phase 2	[18]
POL-6326	DM4OT29	Human immunodeficiency virus infection	1C62	Phase 2	[19]
CTCE-9908	DM95XR8	Sarcoma	2A60-2C35	Phase 1/2	[20]
USL311	DM6HPEC	Recurring respiratory infection	CA07-CA45	Phase 1/2	[2]
ALX-0651	DMIRYM8	Haematological malignancy	2B33.Y	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 4 (CXCR4)	TTBID49	CXCR4_HUMAN	Antagonist	[3]
E-selectin (SELE)	TTAU4D6	LYAM2_HUMAN	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT04197999) A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of GlycoMimetics.
• [4] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [5] Clinical pipeline report, company report or official report of glycomimetics.
• [6] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [7] Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
• [8] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [9] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [12] Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
• [13] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [14] The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [17] Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
• [18] CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
• [19] CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
• [20] A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
• [21] Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.